Erythrocyte pyruvate kinase deficiency: 2015 status report

American Journal of Hematology

Volumn 90, Issue 9, 2015, Pages 825-830

  Grace, Rachael F ^a   Zanella, Alberto ^b   Neufeld, Ellis J ^a   Morton, D Holmes ^c   Eber, Stefan ^d   Yaish, Hassan ^e   Glader, Bertil ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c LANCASTER GENERAL HOSPITAL   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF UTAH   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE SEVERITY; ERYTHROCYTE DISORDER; ERYTHROCYTE PYRUVATE KINASE DEFICIENCY; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; HUMAN; PATIENT CARE; PATIENT MONITORING; PHOTOTHERAPY; PRIORITY JOURNAL; SPLENECTOMY; TREATMENT INDICATION; ADULT; ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC; CHILD; DEFICIENCY; DISEASE MANAGEMENT; ENZYMOLOGY; NEWBORN; PATHOLOGY; PYRUVATE METABOLISM, INBORN ERRORS;

PYRUVATE KINASE;

ADULT; ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC; CHILD; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; EXCHANGE TRANSFUSION, WHOLE BLOOD; HUMANS; INFANT, NEWBORN; PHOTOTHERAPY; PYRUVATE KINASE; PYRUVATE METABOLISM, INBORN ERRORS; SPLENECTOMY;

EID: 84939566700     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24088     Document Type: Article

References (56)

1. Nathan DG, Oski FA, Miller DR, Gardner FH. Life-span and organ sequestration of the red cells in pyruvate kinase deficiency. N Engl J Med 1968;278:73-81.
2. Mentzer WC, J, Baehner, RL, Schmidt-Schonbein H, et al. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest 1971;50:688-699.
3. Warang P, Kedar P, Ghosh K, Colah R. Molecular and clinical heterogeneity in pyruvate kinase deficiency in India. Blood Cells Mol Dis 2013;51:133-137.
4. Pissard S, Max-Audit, I, Skopinski L, et al. Pyruvate kinase deficiency in France: A 3-year study reveals 27 new mutations. Br J Haematol 2006;133:683-689.
5. Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: From genetics to clinical manifestations. Baillieres Best Pract Res Clin Haematol 2000;13:57-81.
6. Baronciani L, Beutler E. Analysis of pyruvate kinase-deficiency mutations that produce nonspherocytic hemolytic anemia. Proc Natl Acad Sci USA 1993;90:4324-4327.
7. Zarza R, Alvarez, R, Pujades A, et al. Molecular characterization of the PK-LR gene in pyruvate kinase deficient Spanish patients. Red Cell Pathology Group of the Spanish Society of Haematology (AEHH). Br J Haematol 1998;103:377-382.
8. Lenzner C, Nurnberg, P, Jacobasch G, et al. Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Blood 1997;89:1793-1799.
9. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 2000;95:3585-3588.
10. Carey PJ, Chandler, J, Hendrick A, et al. Prevalence of pyruvate kinase deficiency in northern European population in the north of England. Northern Region Haematologists Group. Blood 2000;96:4005-4006.
11. Baronciani L, Beutler E. Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia. J Clin Invest 1995;95:1702-1709.
12. Christensen RD, Yaish, HM, Johnson CB, et al. Six children with pyruvate kinase deficiency from one small town: Molecular characterization of the PK-LR gene. J Pediatr 2011;159:695-697.
13. Ayi K, Min-Oo, G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008;358:1805-1810.
14. Ferreira P, Morais, L, Costa R, et al. Hydrops fetalis associated with erythrocyte pyruvate kinase deficiency. Eur J Pediatr 2000;159:481-482.
15. Delivoria-Papadopoulos M, Oski FA, Gottlieb AJ. Oxygen-hemoglobulin dissociation curves: Effect of inherited enzyme defects of the red cell. Science 1969;165:601-602.
16. Oski FA, Marshall, BE, Cohen PJ, et al. The role of the left-shifted or right-shifted oxygen-hemoglobin equilibrium curve. Ann Intern Med 1971;74:44-46.
17. Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. Blood 1962;19:267-295.
18. Lenzner C, Nurnberg, P, Thiele BJ, et al. Mutations in the pyruvate kinase L gene in patients with hereditary hemolytic anemia. Blood 1994;83:2817-2822.
19. Beutler E, Forman L, Rios-Larrain E. Elevated pyruvate kinase activity in patients with hemolytic anemia due to red cell pyruvate kinase "deficiency". Am J Med 1987;83:899-904.
20. Titapiwatanakun R, Hoyer JD, Crain K, Arndt CA. Relative red blood cell enzyme levels as a clue to the diagnosis of pyruvate kinase deficiency. Pediatr Blood Cancer 2008;51:819-821.
21. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: Molecular and clinical aspects. Br J Haematol 2005;130:11-25.
22. Pekrun A, Lakomek, M, Eber S, et al. [Diagnosis of pyruvate kinase deficiency in the presence of an elevated reticulocyte count]. Dtsch Med Wochenschr 1995;120:1620-1624.
23. Zanella A, Fermo, E, Bianchi P, et al. Pyruvate kinase deficiency: The genotype-phenotype association. Blood Rev 2007;21:217-231.
24. Matsumoto N, Ishihara, T, Nakashima K, et al. Sequestration and destruction of reticulocyte in the spleen in pyruvate kinase deficiency hereditary nonspherocytic hemolytic anemia. Nihon Ketsueki Gakkai Zasshi 1972;35:525-537.
25. Rider NL, Strauss, KA, Brown K, et al. Erythrocyte pyruvate kinase deficiency in an old-order Amish cohort: Longitudinal risk and disease management. Am J Hematol 2011;86:827-834.
26. Raphael MF, Van Wijk, R, Schweizer JJ, et al. Pyruvate kinase deficiency associated with severe liver dysfunction in the newborn. Am J Hematol 2007;82:1025-1028.
27. Boivin P, Ottenwaelter T. [Hereditary haemolytic anaemia due to pyruvate kinase deficiency. Prognosis of neonatal forms (author's transl)]. Nouv Presse Med 1982;11:917-919.
28. Necheles TF, Finkel HE, Sheehan RG, Allen DM. Red cell pyruvate kinase deficiency. The effect of splenectomy. Arch Intern Med 1966;118:75-78.
29. Zanella A, Bianchi P, Fermo E. Pyruvate kinase deficiency. Haematologica 2007;92:721-723.
30. Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol 2001;67:197-199.
31. Sandoval C, Stringel G, Weisberger J, Jayabose S. Failure of partial splenectomy to ameliorate the anemia of pyruvate kinase deficiency. J Pediatr Surg 1997;32:641-642.
32. Diesen DL, Zimmerman, SA, Thornburg CD, et al. Partial splenectomy for children with congenital hemolytic anemia and massive splenomegaly. J Pediatr Surg 2008;43:466-472.
33. Rice HE, Oldham, KT, Hillery CA, et al. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg 2003;237:281-288.
34. Morimoto M, Kanno, H, Asai H, et al. Pyruvate kinase deficiency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Blood 1995;86:4323-4330.
35. Tanphaichitr VS, Suvatte, V, Issaragrisil S, et al. Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency. Bone Marrow Transplant 2000;26:689-690.
36. Zanella A, Berzuini A, Colombo MB, et al. Iron status in red cell pyruvate kinase deficiency: Study of Italian cases. Br J Haematol 1993;83:485-490.
37. Marshall SR, Saunders PW, Hamilton PJ, Taylor PR. The dangers of iron overload in pyruvate kinase deficiency. Br J Haematol 2003;120:1090-1091.
38. Zanella A, Bianchi P, Iurlo A, et al. Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: Study of Italian cases. Blood Cells Mol Dis 2001;27:653-661.
39. Finkenstedt A, Bianchi, P, Theurl I, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol 2009;144:789-793.
40. Deeren D. Deferasirox in pyruvate kinase deficiency. Ann Hematol 2009;88:397.
41. Dolan LM, Ryan M, Moohan J. Pyruvate kinase deficiency in pregnancy complicated by iron overload. Bjog 2002;109:844-846.
42. Fanning J, Hinkle RS. Pyruvate kinase deficiency hemolytic anemia: Two successful pregnancy outcomes. Am J Obstet Gynecol 1985;153:313-314.
43. Amankwah KS, Dick BW, Dodge S. Hemolytic anemia and pyruvate kinase deficiency in pregnancy. Obstet Gynecol 1980;55:42S-44S.
44. Wax JR, Pinette MG, Cartin A, Blackstone J. Pyruvate kinase deficiency complicating pregnancy. Obstet Gynecol 2007;109:553-555.
45. Rutgers MJ, van der Lugt PJ, van Turnhout JM. Spinal cord compression by extramedullary hemopoietic tissue in pyruvate-kinase-deficiency-caused hemolytic anemia. Neurology 1979;29:510-513.
46. Hipkins R, Thompson, J, Naidoo P, et al. Images in haematology. Paravertebral extramedullary haemopoiesis associated with pyruvate kinase deficiency. Br J Haematol 2009;147:275.
47. Muller-Soyano A, Tovar de Roura, E, Duke PR, et al. Pyruvate kinase deficiency and leg ulcers. Blood 1976;47:807-813.
48. Ryan C, Percy M, O'Brien D, et al. Myelodysplastic syndrome in a patient with hereditary pyruvate kinase deficiency. Hematol J 2004;5:91-92.
49. Vives-Corrons JL, Florensa L, Muncunill J, et al. Chronic myelomonocytic leukemia associated with hereditary pyruvate kinase deficiency and multiple acquired erythrocyte abnormalities. Acta Haematol 1979;61:168-174.
50. Tani K, Yoshikubo T, Ikebuchi K, et al. Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: Implications for gene therapy of human PK deficiency. Blood 1994;83:2305-2310.
51. Kanno H, Utsugisawa, T, Aizawa S, et al. Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency. Haematologica 2007;92:731-737.
52. Zanella A, Rebulla P, Giovanetti AM, et al. Effects of sulphydryl compounds on abnormal red cell pyruvate kinase. Br J Haematol 1976;32:373-385.
53. Blume KG, Arnold H, Hasslinger K, Lohr GW. Effect of riboflavin treatment on human red cell pyruvate kinase deficiency. Clin Chim Acta 1976;71:331-334.
54. Staal GE, van Berkel TJ, Nijessen JG, Koster JF. Normalisation of red blood cell pyruvate kinase in pyruvate kinase deficiency by riboflavin treatment. Clin Chim Acta 1975;60:323-327.
55. Yang H, Merica E, Chen Y, et al. Phase 1 single (SAD) and multiple (MAD) ascending dose studies of the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of AG-348, a first-in- -class allosteric activator of pyruvate kinase-R, in healthy subjects. Am Soc Hematol 2014;124:4007.
56. Kung C, Hill, C, Chen Y, et al. AG-348 activation of pyruvate kinase in vivo enhances red cell glycolysis in mice. Am Soc Hematol, 2014;124:4010.